Regulation of the Nrf2-keap1 antioxidant response by the ubiquitin proteasome system: An insight into cullin-ring ubiquitin ligases

Antioxidants and Redox Signaling

Volumn 13, Issue 11, 2010, Pages 1699-1712

  Villeneuve, Nicole F ^a   Lau, Alexandria ^a   Zhang, Donna D ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CAND1 PROTEIN; CULLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CANCER THERAPY; CELL ACTIVITY; CELL AGING; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; DIMERIZATION; DNA REPAIR; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIOXIDANTS; CULLIN PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 77958115724     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3211     Document Type: Review

References (105)

1. Aberle H, Bauer A, Stappert J, Kispert A, and Kemler R. beta-catenin is a target for the ubiquitin-proteasome path-way. EMBOJ 16: 3797-3804, 1997.
2. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, and Alkalay I. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: A molecu-lar switch for the Wnt pathway. Genes Dev 16: 1066-1076, 2002.
3. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, and Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443: 590-593, 2006.
4. Cardoso F, Ross JS, Picart MJ, Sotiriou C, and Durbecq V. Targeting the ubiquitin-proteasome pathway in breast can-cer. Clin Breast Cancer 5: 148-157, 2004.
5. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 19: 404-413, 2009.
6. Cheng Y, Dai X, and Zhao Y. AtCAND1, a HEAT-repeat protein that participates in auxin signaling in Arabidopsis. Plant Physiol 135: 1020-1026, 2004.
7. Chew EH, Poobalasingam T, Hawkey CJ, and Hagen T. Characterization of cullin-based E3 ubiquitin ligases in intact mammalian cells\Evidence for cullin dimerization. Cell Signal 19: 1071-1080, 2007.
8. Chuang LY, Guh JY, Liu SF, Hung MY, Liao TN, Chiang TA, Huang JS, Huang YL, Lin CF, and Yang YL. Regulation of type II transforming-growth-factor-beta receptors by protein kinase C iota. Biochem J 375: 385-393, 2003.
9. Cope GA and Deshaies RJ. COP9 signalosome: A multi-functional regulator of SCF and other cullin-based ubiquitin ligases. Cell 114: 663-671, 2003.
10. Cope GA and Deshaies RJ. Targeted silencing of Jab1/Csn5 in human cells downregulates SCF activity through reduction of F-box protein levels. BMC Biochem 7: 1, 2006.
11. Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, and Deshaies RJ. Role of predicted metallopro-tease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298: 608-611, 2002.
12. Dias DC, Dolios G, Wang R, and Pan ZQ. CUL7: A DOC domain-containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex. Proc Natl Acad Sci USA 99:16601-1666, 2002.
13. Dixon C, Brunson LE, Roy MM, Smothers D, Sehorn MG, and Mathias N. Overproduction of polypeptides corre-sponding to the amino terminus of the F-box proteins Cdc4p and Met30p inhibits ubiquitin ligase activities of their SCF complexes. Eukaryot Cell 2: 123-133, 2003.
14. Dohmann EM, Kuhnle C, and Schwechheimer C. Loss of the CONSTITUTIVE PHOTOMORPHOGENIC9 signalo-some subunit 5 is sufficient to cause the cop/det/fus mutant phenotype in Arabidopsis. Plant Cell 17: 1967-1978, 2005.
15. Doronkin S, Djagaeva I, and Beckendorf SK. The COP9 signalosome promotes degradation of Cyclin E during early Drosophila oogenesis. Dev Cell 4: 699-710, 2003.
16. Dubiel W. Resolving the CSN and CAND1 paradoxes. Mol Cell 35: 547-549, 2009.
17. Ehrlich ES, Wang T, Luo K, Xiao Z, Niewiadomska AM, Martinez T, Xu W, Neckers L, and Yu XF. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci USA 106: 20330-20335, 2009.
18. Feng S, Shen Y, Sullivan JA, Rubio V, Xiong Y, Sun TP, and Deng XW. Arabidopsis CAND1, an unmodified CUL1-interacting protein, is involved in multiple devel-opmental pathways controlled by ubiquitin/proteasome-mediated protein degradation. Plant Cell 16: 1870-1882, 2004.
19. Fuchs SY, Spiegelman VS, and Kumar KG. The many faces of beta-TrCP E3 ubiquitin ligases: Reflections in the magic mirror of cancer. Oncogene 23: 2028-2036, 2004.
20. Ghosh S and Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8: 837-848, 2008.
21. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, and Linehan WM. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93: 10589-10594, 1996.
22. Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K, Kisselev AF, Harel-Bellan A, and Nakatani Y. CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between comple-mentation factors of the Cockayne syndrome. Genes Dev 20: 1429-1434, 2006.
23. Gusmaroli G, Feng S, and Deng XW. The Arabidopsis CSN5A and CSN5B subunits are present in distinct COP9 signalo-some complexes, and mutations in their JAMM domains exhibit differential dominant negative effects on develop-ment. Plant Cell 16: 2984-3001, 2004.
24. Hannah J and Zhou P. Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases. DNA Repair (Amst) 8: 536-543, 2009.
25. Hayden MS and Ghosh S. Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
26. Hayes JD and McMahon M. Molecular basis for the contri-bution of the antioxidant responsive element to cancer che-moprevention. Cancer Lett 174: 103-113, 2001.
27. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
28. He Q, Cheng P, He Q, and Liu Y. The COP9 signalosome regulates the Neurospora circadian clock by controlling the stability of the SCFFWD-1 complex. Genes Dev 19: 1518-1531, 2005.
29. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 30: 405-439, 1996.
30. Hoeller D and Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444, 2009.
31. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Jr., and Gold-berg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93: 10595-10599, 1996.
32. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through bind-ing to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
33. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, and Pause A. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96: 12436-12441, 1999.
34. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gas-kell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
35. Jeong WS, Jun M, and Kong AN. Nrf2: A potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 8: 99-106, 2006.
36. Kaelin WG, Jr. Cancer. Many vessels, faulty gene. Nature 399: 203-204, 1999.
37. Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW, and Nakayama KI. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18: 3055-3065, 2004.
38. Kapelari B, Bech-Otschir D, Hegerl R, Schade R, Dumdey R, and Dubiel W. Electron microscopy and subunit-subunit interaction studies reveal a first architecture of COP9 sig-nalosome. J Mol Biol 300: 1169-1178, 2000.
39. Kawakami T, Chiba T, Suzuki T, Iwai K, Yamanaka K, Minato N, Suzuki H, Shimbara N, Hidaka Y, Osaka F, Omata M, and Tanaka K. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 20: 4003-4012, 2001.
40. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
41. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, and Lee SH. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220: 446-451, 2010.
42. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, and Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 li-gase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130-7139, 2004.
43. Kobayashi M and Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reac-tive oxygen species. Adv Enzyme Regul 46: 113-140, 2006.
44. Kominami K, Ochotorena I, and Toda T. Two F-box/WD-repeat proteins Pop1 and Pop2 form hetero-and homo-complexes together with cullin-1 in the fission yeast SCF (Skp1-Cullin-1-F-box) ubiquitin ligase. Genes Cells 3: 721-735, 1998.
45. Kwong LN and Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 656: 85-106, 2009.
46. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
47. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, and Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6: 182-188, 2007.
48. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC, Li CW, Ding Q, Liao TL, Lai CC, Lin AC, Chang YH, Tsai SF, Li LY, and Hung MC. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 36: 131-140, 2009.
49. Lee J and Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 26: 775-780, 2007.
50. Li W and Ye Y. Polyubiquitin chains: Functions, structures, and mechanisms. Cell Mol Life Sci 65: 2397-2406, 2008.
51. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, and He X. Control of beta-catenin phosphoryla-tion/degradation by a dual-kinase mechanism. Cell 108: 837-847, 2002.
52. Lo SC and Hannink M. CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1. Mol Cell Biol 26: 1235-1244, 2006.
53. Lyapina S, Cope G, Shevchenko A, Serino G, Tsuge T, Zhou C, Wolf DA, Wei N, Shevchenko A, and Deshaies RJ. Pro-motion of NEDD-CUL1 conjugate cleavage by COP9 sig-nalosome. Science 292: 1382-1385, 2001.
54. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Ri-chard V, Thomas D, Strebel K, and Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1: 565-574, 1998.
55. Matsuzawa SI and Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7: 915-926, 2001.
56. McMahon M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mech-anism: A two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 281: 24756-24768, 2006.
57. Merlet J, Burger J, Gomes JE, and Pintard L. Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and di-merization. Cell Mol Life Sci 66: 1924-1938, 2009.
58. Min KW, Kwon MJ, Park HS, Park Y, Yoon SK, and Yoon JB. CAND1 enhances deneddylation of CUL1 by COP9 signa-losome. Biochem Biophys Res Commun 334: 867-874, 2005.
59. Motohashi H and Yamamoto M. Nrf2-Keap1 defines a phys-iologically important stress response mechanism. Trends Mol Med 10: 549-557, 2004.
60. Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoe K, Good RA, and Nakayama KI. Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA 100: 8752-8757, 2003.
61. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, and Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773-786, 2005. (Pubitemid 41721026)
62. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, and Kaelin WG, Jr. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep 3: 177-182, 2002.
63. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, and Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008.
64. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, Kouzmenko A, Nohara K, Chiba T, Fujii-Kuriyama Y, and Kato S. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562-566, 2007.
65. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, and Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One 1: e128, 2006.
66. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700, 2006.
67. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, and Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156-2161, 1997.
68. Peth A, Berndt C, Henke W, and Dubiel W. Downregulation of COP9 signalosome subunits differentially affects the CSN complex and target protein stability. BMC Biochem 8: 27, 2007.
69. Petroski MD and Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6: 9-20, 2005.
70. Pintard L, Kurz T, Glaser S, Willis JH, Peter M, and Bo-werman B. Neddylation and deneddylation of CUL-3 is re-quired to target MEI-1/Katanin for degradation at the meiosis-to-mitosis transition in C. elegans. Curr Biol 13: 911-921, 2003.
71. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, and Chau V. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 97: 4579-4584, 2000.
72. Popov N, Herold S, Llamazares M, Schulein C, and Eilers M. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle 6: 2327-2331, 2007.
73. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, and Eilers M. The ubi-quitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 9: 765-774, 2007. (Pubitemid 47019463)
74. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V, and Palombella VJ. Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol 20: 2326-2333, 2000.
75. Sarikas A, Xu X, Field LJ, and Pan ZQ. The cullin7 E3 ubi-quitin ligase: A novel player in growth control. Cell Cycle 7: 3154-3161, 2008.
76. Schmidt MW, McQuary PR, Wee S, Hofmann K, and Wolf DA. F-box-directed CRL complex assembly and regulation by the CSN and CAND1. Mol Cell 35: 586-597, 2009.
77. Seibert V, Prohl C, Schoultz I, Rhee E, Lopez R, Abderazzaq K, Zhou C, and Wolf DA. Combinatorial diversity of fission yeast SCF ubiquitin ligases by homo-and heterooligomeric assemblies of the F-box proteins Pop1p and Pop2p. BMC Biochem 3: 22, 2002.
78. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, and Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to che-motherapy in gallbladder cancer. Gastroenterology 135: 1358-1368, 2008.
79. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, and Hirohashi S. Cancer re-lated mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
80. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, and Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related fac-tor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
81. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
82. Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, McDonald ER, 3rd, Li MZ, Hannon GJ, Sorger PK, Kirschner MW, Harper JW, and Elledge SJ. Anaphase initi-ation is regulated by antagonistic ubiquitination and deu-biquitination activities. Nature 446: 876-881, 2007.
83. Sugasawa K, Okuda Y, Saijo M, Nishi R, Matsuda N, Chu G, Mori T, Iwai S, Tanaka K, Tanaka K, and Hanaoka F. UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 121: 387-400, 2005.
84. Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 8: 501-511, 2008.
85. Suzuki H, Chiba T, Suzuki T, Fujita T, Ikenoue T, Omata M, Furuichi K, Shikama H, and Tanaka K. Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to Ikappa-Balpha for signal-dependent ubiquitination. J Biol Chem 275: 2877-2884, 2000.
86. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, and Ya-mamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition model. Mol Cell Biol 26: 2887-2900, 2006.
87. Tong KI, Kobayashi A, Katsuoka F, and Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism. Biol Chem 387: 1311-1320, 2006.
88. Wada H, Yeh ET, and Kamitani T. Identification of NEDD8-conjugation site in human cullin-2. Biochem Biophys Res Commun 257: 100-105, 1999.
89. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, and Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243, 2008.
90. Wee S, Geyer RK, Toda T, and Wolf DA. CSN facilitates Cullin-RING ubiquitin ligase function by counteracting au-tocatalytic adapter instability. Nat Cell Biol 7: 387-391, 2005.
91. Wimuttisuk W, Singer JD. The Cullin3 ubiquitin ligase functions as a Nedd8-bound heterodimer. Mol Biol Cell 18: 899-909, 2007.
92. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F, and Krek W. The F-box protein Skp2 is a ubi-quitylation target of a Cul1-based core ubiquitin ligase complex: Evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J 19: 5362-5375, 2000.
93. Wolf DA, McKeon F, and Jackson PK. F-box/WD-repeat pro-teins pop1p and Sud1p/Pop2p form complexes that bind and direct the proteolysis of cdc18p. Curr Biol 9: 373-376,1999.
94. Wu JT, Lin HC, Hu YC, and Chien CT. Neddylation and deneddylation regulate Cul1 and Cul3 protein accumula-tion. Nat Cell Biol 7: 1014-1020, 2005.
95. Wu K, Chen A, and Pan ZQ. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem 275: 32317-32324, 2000.
96. Xu C, Kim NG, and Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 8: 4032-4039, 2009.
97. Yang X, Menon S, Lykke-Andersen K, Tsuge T, Di X, Wang X, Rodriguez-Suarez RJ, Zhang H, and Wei N. The COP9 signalosome inhibits p27(kip1) degradation and impedes G1-S phase progression via deneddylation of SCF Cul1. Curr Biol 12: 667-672, 2002.
98. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, Manning AM, Ciechanover A, and Ben-Neriah Y. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J 16: 6486-6494, 1997.
99. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38: 769-789, 2006.
100. Zhang DD, Lo SC, Cross JV, Templeton DJ, and Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941-10953, 2004.
101. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, and Hannink M. Ubiquitination of Keap1, a BTB-Kelch sub-strate adaptor protein for Cul3, targets Keap1 for degra-dation by a proteasome-independent pathway. J Biol Chem 280: 30091-30099, 2005.
102. Zheng J, Yang X, Harrell JM, Ryzhikov S, Shim EH, Lykke-Andersen K, Wei N, Sun H, Kobayashi R, and Zhang H. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell 10: 1519-1526, 2002.
103. Zhou C, Wee S, Rhee E, Naumann M, Dubiel W, and Wolf DA. Fission yeast COP9/signalosome suppresses cullin activity through recruitment of the deubiquitylating en-zyme Ubp12p. Mol Cell 11: 927-938, 2003.
104. Zhou P and Howley PM. Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. Mol Cell 2: 571-580, 1998.
105. Zipper LM and Mulcahy RT. The Keap1 BTB/POZ di-merization function is required to sequester Nrf2 in cyto-plasm. J Biol Chem 277: 36544-36552, 2002